we answer every e-mail
Stock Picks top stocks hot stocks best stock picks best stocks daily picks invest in stocks
research stock About Us A1 Stock Testimonials Stock Trading Tips Stock Terminology Order A1 Stock Services Contact Us investing
daily stock picks
the best stock picks
Member login
Stock Picks, Best Stock Picks, Top Stocks | Hot Stocks
stock market predictions
Stock Picks, Best Stock Picks, Top Stocks | Hot Stocks
Stock advice
Stock Picks, Best Stock Picks, Top Stocks | Hot Stocks
stock picks
Order Now

15 years

Stock Picks, Best Stock Picks, Top Stocks | Hot Stocks
The Best Stock Picks
Click Here To See A Sample Of Our Picks           Testimonials

Get top stocks daily
We make daily picks to make you the most money in a shortest amount of time possible. We are committed to picking the best stocks that are ready to advance while providing the best customer service possible. Our success proves we are the number one choice for your investment.
We research thousands of the best stocks
We research stock to find those that are ready to advance and make gains for you. We then post them on our web site each night. They are easy to follow and understand!
We never buy picks before our clients
This is known as "Pump And Dump" and we will not do this to our customers! We buy the stock the same time our customers do, following our own stock market predictions!
We are not paid to suggest our picks
We will not accept any payment from companies or marketing firms to suggest their stock to our customers.
Easy to follow and understand
We post our stock analysis picks on our web site each night instructing you on which stocks to buy, entry price, stop loss, exit price and why we have chosen pick. Everything you need will be listed in an easy to follow format. We take the guess work out of Investing.
We also post our past picks history for you to see. For more information on stock analysis, check out our stock trading tips and stock terminology pages.
No obligation and you may cancel at any time
We do not hold you to a one year contract! We bill by the month allowing you to test out our stock market advice with no long term commitment.
Our honest History for all of our picks says it all
Our History Page, which will list our picks for the last five years, shows everything. We hide nothing in our history. We show the winners along with the losers.


Order Now

Special Offer


the best investment advice
  Special Offer  
  Sign up now and you will also receive full access to Affordable Stock's daily Penny Investments. That's two subscriptions for the price of one.

  Click Here for more details  


great customer service


Stock Report For Week Ended July 25, 2014

Stocks mixed as investors weigh conflicting signals

The major benchmarks ended mixed for the week as investors weighed conflicting signals about the economy and corporate earnings. The Standard & Poor's 500 Index touched a new high on Thursday before falling back to end the week, while the price-weighted Dow Jones Industrial Average fared worst due to poor performance of several components. The technology-laden Nasdaq Composite performed best, helped by a rebound in biotechnology shares. Small-cap stocks lagged mid- and large-caps.

Earnings appear to have grown faster than expected in Q2

After a mild stumble on Monday, stocks managed to advance through most of the week, helped by a generally positive tone to the week's many second-quarter earnings reports. Analytical firm FactSet reported that, by Friday, overall earnings for companies in the S&P 500 that had reported so far this quarter had increased by 6.7%, well above the 4.9% growth expected before the reporting season began. Moreover, over three-quarters of the companies that had reported in the second quarter to date had surpassed analysts' earnings estimates.

Biotech sector surges on trial results

Major companies in several industries managed to top expectations during the week, but the biotechnology sector got a particular boost on Wednesday morning. Biotech stocks had suffered a severe sell-off in March and April and, while they had recovered much of their losses since, appeared headed for another downturn in early July. Part of the selling pressure may have been due to comments from Federal Reserve officials, who remarked that valuations appeared "stretched" for smaller biotech firms.

Financial results for biotech firms can swing wildly based on clinical results, drug approvals, and other factors, however. This was illustrated during the week by Puma Technologies, which rose 300% at one point on Wednesday following news that its breast cancer drug had shown promise in clinical trials. Regarding cancer treatments more generally, T. Rowe Price Health Sciences Fund Manager Taymour Tamaddon believes that we will uncover highly effective therapies in the next decade. He is particularly excited about new drugs that enable the immune system to play a larger role in cancer therapy.

Disappointments weigh on stocks to end the week

Investors proved less enthusiastic about some major earnings reports following the close of trading on Thursday, however, which helped spark a sharp market decline on Friday. Most notably, Amazon reported a strong increase in revenue but larger-than-anticipated expenses, and the heavily weighted company drove many of the indexes lower.

Housing sector held back by low pace of household formation

Economic data also proved less encouraging as the week progressed. This pattern was particularly true in housing data, as initial enthusiasm over a solid rise in existing home sales, reported Tuesday, was offset by news on Thursday that sales of new homes had fallen sharply in June. T. Rowe Price Chief Economist Alan Levenson notes that new construction has been limited by the disappointing pace of household formation relative to job growth.


Stock Picks | Best Stock Picks | Buy Stocks
Top Stocks | Hot Stock Picks | Hot Stocks

Site Map © 1999-2013 All Rights Reserved Buy Stocks
Penny Stock Picks